Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02193867 · ClinicalTrials.gov registry record · Phase 2
Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02193867 is a Phase 2 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 10 participants.
The verdict
NCT02193867, a Phase 2 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This was an open-label, repeat-dose, study of sebelipase alfa in infants with rapidly progressive lysosomal acid lipase deficiency (LAL-D). Eligible participants received once-weekly infusions of sebelipase alfa for up to 3 years.
Interventions
- DRUG Sebelipase Alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-06-06 |
| Est. Completion | 2018-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02193867
The ClinicalTrials.gov registry entry for NCT02193867 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sebelipase Alfa is the first listed.
NCT02193867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02193867 about?
NCT02193867 is a clinical study titled "Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency". This was an open-label, repeat-dose, study of sebelipase alfa in infants with rapidly progressive lysosomal acid lipase deficiency (LAL-D). Eligible participants received once-weekly infusions of sebelipase alfa for up to 3 years.
What is the current status of trial NCT02193867?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2014-06-06. Estimated completion is 2018-10-30.
What interventions are being tested in trial NCT02193867?
The interventions under investigation include: Sebelipase Alfa (DRUG).
Who is sponsoring clinical trial NCT02193867?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.